These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
18. The Impact of Exacerbation History on the Safety and Efficacy of Aclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial. Wise RA; Chapman KR; Scirica BM; Daoud SZ; Lythgoe D; Garcia-Gil E Int J Chron Obstruct Pulmon Dis; 2021; 16():689-699. PubMed ID: 33776428 [TBL] [Abstract][Full Text] [Related]
19. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Vestbo J; Anderson JA; Brook RD; Calverley PM; Celli BR; Crim C; Martinez F; Yates J; Newby DE; Lancet; 2016 Apr; 387(10030):1817-26. PubMed ID: 27203508 [TBL] [Abstract][Full Text] [Related]
20. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease. Maqsood U; Ho TN; Palmer K; Eccles FJ; Munavvar M; Wang R; Crossingham I; Evans DJ Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012930. PubMed ID: 30839102 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]